The Trial
Welcome to the Scandinavian Candesartan Acute Stroke Trial (SCAST)!

Scandinavian Candesartan Acute Stroke Trial (SCAST) is a multi-centre, randomised- and placebo-controlled, double blind trial of the angiotensin receptor blocker candesartan in patients with acute stroke and elevated blood pressure.

SCAST is funded by the Norwegian Health Authorities, AstraZeneca, Takeda, and Ullevaal University Hospital in Oslo.

The trial began in June 2005. Patient recruitment was stopped in February 2010, at 2,026 patients.